Clinical bottom line
Rare inherited immunodeficiency syndromes with immune dysregulation represent a complex group of disorders characterized by combined defects in immune defense and immune tolerance. These syndromes often manifest with recurrent infections alongside autoimmune phenomena or lymphoproliferation. Current evidence highlights the importance of early recognition, genetic diagnosis, and tailored immunomodulatory therapies to mitigate morbidity. Immunotherapy approaches, including targeted cytokine blockade and hematopoietic stem cell transplantation (HSCT), show promise but require individualized risk-benefit assessment. Clinicians should maintain a high index of suspicion for immune dysregulation in patients with unusual infection-autoimmunity overlap and consider multidisciplinary management strategies.
What the evidence shows
Inherited immunodeficiency syndromes with immune dysregulation encompass disorders such as autoimmune lymphoproliferative syndrome (ALPS), immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, and certain combined immunodeficiencies with autoimmunity (Ochs et al., 2013). These syndromes arise from genetic defects affecting immune cell development, apoptosis, or regulatory pathways, leading to impaired pathogen clearance and loss of self-tolerance.
Autoantibody production is a hallmark feature in many of these conditions, reflecting the Janus-faced nature of immune dysregulation where immune deficiency coexists with autoimmunity (Wang et al., 2022). The presence of autoantibodies can contribute to clinical manifestations such as cytopenias, endocrinopathies, and organ-specific autoimmune damage.
Immunotherapy strategies have evolved beyond broad immunosuppression to include targeted approaches. For example, blockade of cytokines like interleukin-1 or tumor necrosis factor-alpha may ameliorate inflammatory symptoms without severely compromising host defense. HSCT remains the only curative option for many severe syndromes but carries significant risks and requires careful patient selection (Ochs et al., 2013).
The pathophysiology of immune dysregulation in these syndromes shares features with myelodysplastic syndromes (MDS), where immune-mediated bone marrow failure and autoimmunity complicate management (Symeonidis et al., 2016; unnamed 2008 source). This overlap suggests that insights from MDS immunotherapy may inform treatment of inherited immunodeficiencies with immune dysregulation.
Genetic counseling is essential for affected families due to the hereditary nature of these syndromes and implications for family planning (Yelland et al., 2004). Early genetic diagnosis facilitates prognostication and guides therapeutic decisions.
Caveats and uncertainty
The rarity and heterogeneity of inherited immunodeficiency syndromes with immune dysregulation limit the availability of large-scale clinical trials. Much of the evidence derives from case series, expert consensus, and extrapolation from related disorders. Consequently, treatment recommendations remain largely empirical and individualized.
The balance between immunosuppression to control autoimmunity and preservation of immune competence to prevent infections is delicate and not fully elucidated. Long-term outcomes of emerging targeted immunotherapies in this population are unknown.
HSCT outcomes vary widely depending on the underlying genetic defect, conditioning regimen, and donor availability. The risk of graft-versus-host disease and transplant-related mortality necessitates careful risk stratification.
Autoantibody profiles and biomarkers predictive of disease course or therapeutic response require further validation to inform clinical decision-making.
How this may change practice
Clinicians managing patients with recurrent infections and autoimmune manifestations should consider inherited immunodeficiency syndromes with immune dysregulation in their differential diagnosis. Early referral for genetic evaluation and immunological workup is warranted.
Integration of targeted immunotherapies into treatment algorithms may improve symptom control and reduce reliance on broad immunosuppression, potentially lowering infection risk. Multidisciplinary collaboration among immunologists, hematologists, geneticists, and transplant specialists is critical.
Awareness of the overlap between immune dysregulation in inherited immunodeficiencies and MDS may prompt consideration of immunomodulatory agents used in MDS for select patients.
Genetic counseling should be incorporated routinely to inform patients and families about inheritance patterns, recurrence risks, and reproductive options.
Ongoing research and clinical trials are needed to establish evidence-based guidelines and optimize therapeutic strategies.